We appreciate the opportunity to respond to each of the points raised by Cleland et al as follows: First, we reject the implication that patient care focused on CRT rather than appropriate pharmacological therapy. In fact, all patients were on maximum tolerated medical therapy and were referred for a CRT device following careful clinical review and met accepted implant criterion. The fact that many patients could not tolerate higher doses …